A Patient with De Novo Tuberculosis during Anti-Tumor Necrosis Factor-- Therapy Illustrating Diagnostic Pitfalls and Paradoxical Response to Treatment-Reference-Cited by-同舟云学术

A Patient with De Novo Tuberculosis during Anti-Tumor Necrosis Factor-- Therapy Illustrating Diagnostic Pitfalls and Paradoxical Response to Treatment

Published:2007-12-01 Issue:11 Volume:45 Page:1470-1475
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clinical Infectious Diseases

Author:

Arend S. M.,Leyten E. M. S.,Franken W. P. J.,Huisman E. M.,van Dissel J. T.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/45/11/1470/956182/45-11-1470.pdf

Reference42 articles.

1. Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

2. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic

3. Paradoxical Response to Antituberculous Therapy in Infliximab-Treated Patients with Disseminated Tuberculosis

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chapitre 10: Le traitement de la tuberculose active chez les populations particulières;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2023-11-02

2. Modulating macrophage function to reinforce host innate resistance against Mycobacterium avium complex infection;Frontiers in Immunology;2022-11-24

3. Chapter 10: Treatment of active tuberculosis in special populations;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2022-03-24

4. Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors;Translational Cancer Research;2022-03

5. The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex;Frontiers in Immunology;2021-01-22